Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
2.875
-0.025 (-0.86%)
At close: Sep 28, 2026, 4:00 PM EDT
2.880
+0.005 (0.17%)
After-hours: Sep 28, 2026, 7:50 PM EDT
Prime Medicine Market Cap
Prime Medicine has a market cap or net worth of $511.47 million as of September 28, 2026. Its market cap has decreased by -40.90% in one year.
Market Cap
511.47M
Enterprise Value
528.88M
1-Year Change
-40.90%
Ranking
Category
Stock Price
$2.88
ChartMarket Cap Chart
Since the IPO on October 20, 2022, Prime Medicine's market cap has decreased from $1.63B to $511.47M, a decrease of -68.57%. That is a compound annual growth rate of -25.44%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 28, 2026 | 511.47M | -16.74% |
| Dec 31, 2025 | 614.32M | 64.88% |
| Dec 31, 2024 | 372.58M | -54.41% |
| Dec 29, 2023 | 817.15M | -49.22% |
| Dec 30, 2022 | 1.61B | -1.12% |
| Oct 20, 2022 | 1.63B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Eupraxia Pharmaceuticals | 527.23M |
| AgomAb Therapeutics NV | 517.60M |
| Bright Minds Biosciences | 515.74M |
| Indaptus Therapeutics | 512.98M |
| Puma Biotechnology | 504.33M |
| Arvinas | 496.28M |
| Autolus Therapeutics | 493.73M |
| REGENXBIO | 488.50M |